Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

(2013) E. J. Rhee et al.   DIABETES OBESITY & METABOLISM

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug–Drug Interaction Study in Healthy Male Korean Volunteers

(2012) Yook-Hwan Noh et al.   CLINICAL THERAPEUTICS

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes

(2012) S. J. Yang et al.   DIABETES OBESITY & METABOLISM

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers

(2011) Sung Eun Kim et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

(2010) E. J. Rhee et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers

(2009) Kyoung Soo Lim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

(2008) Kyoung Soo Lim et al.   CLINICAL THERAPEUTICS

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function

(2008) Kei Ohnuma et al.   TRENDS IN IMMUNOLOGY